Poster PO3-16-11

Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe

Peter S Hall,^{1,2} Sue Cheeseman,³ Paul Cottu,⁴ Markus Krebs,⁵ Christian W Scholz,⁶ Emilio Bria,⁷ Armando Orlandi,⁷ Nuria Ribelles,⁸ Mahéva Vallet,^{1,2} Nicolas Niklas,⁹ Catherine Hogg,¹⁰ Markus Lucerna,¹¹ Simon M Collin,¹² Amanda Logue,¹³ Gráinne Long¹²

University of Edinburgh, UK; ²Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, UK; ³Leeds Teaching Hospitals NHS Trust, UK; ⁴Department of Medical Oncology, Institut Curie, Paris, France; ⁵Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Germany; ⁶Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany; ⁷Agostino Gemelli University Policlinic, Rome, Italy; ⁸Hospital Universitario Virgen de la Victoria de Málaga, Spain; ⁹IQVIA, Frankfurt, Germany; ¹⁰IQVIA, London, UK; ¹¹Daiichi Sankyo Europe GmbH, Munich, Germany; ¹²Global Medical Affairs, Evidence Generation & External Alliances, Oncology Outcomes Research, OBU Medical, AstraZeneca, Cambridge, UK; ¹³Global Medical Affairs, Regional Medical Affairs, OBU Medical, AstraZeneca, Cambridge, UK

Objectives

- To understand and characterize contemporary attrition rates (percentage of patients who completed a line of therapy [LOT] but did not receive the subsequent LOT) after first-line (1L) and second-line (2L) therapy among women with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) receiving routine care at selected oncology centers in EU4 countries (France, Germany, Italy, and Spain) and the UK
- To highlight the potential lost opportunity for patients with HER2+ mBC to benefit from optimal targeted treatments at the earliest indicated LOT

Conclusions

- These data from routine clinical practice in EU4 countries and the UK indicate that 29.6% and 34.2% of patients with HER2+ mBC who completed 1L and 2L therapy, respectively, did not receive a subsequent LOT, which was primarily due to death, move to end-of-life palliative care, loss to follow up (FU), and 'other' reasons for attrition; this highlights the importance of using optimal HER2-directed treatments in the earliest indicated setting
- Further research is needed to understand the high variation in reasons for attrition, as this may reflect differences in patient fitness, clinician and patient attitudes to treatment, and access to treatments across centers
- Future analyses for this study will focus on characterizing treatment patterns and real-world outcomes

Plain language summary



Why did we perform this research?

In some people with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) (cancer that has spread from its original site), the first (or first-line [1L]) treatment they are given either does not work or eventually stops working, and they need a different option (a second-line [2L] treatment). Some people who receive a 2L treatment may also need a third-line treatment. We performed this study to identify people in the real world who complete a 1L or 2L treatment but do not receive additional medication (the attrition rate) and the reasons why this can occur.



How did we perform this research?

We used an existing database of medical records to obtain information about treatments and outcomes of people in France, Germany, Italy, Spain, and the UK. We focused on women across Europe between 2017 and 2021 with HER2-positive mBC.



What were the findings of this research?

We found that some women with HER2-positive mBC completed 1L (29.6%) and 2L (34.2%) treatment but did not receive a subsequent treatment. This was primarily due to death, transfer to end-of-life medical care (eg hospice), loss to follow up, and 'other' reasons for attrition.



What are the implications of this research?

This study highlights the importance of choosing the most effective drugs as early as possible to treat people with HER2-positive mBC and systematically documenting the causes of attrition at each line of treatment to understand why some people are not offered the most effective drugs.





ntary material

Please scan this quick response (QR) code with your smartphone camera or app to obtain a copy of these materials. Alternatively, access at: https://bit.ly/408XKdq

Copies of this poster obtained through this QR code are for personal use only and may not be reproduced without permission from SABCS[®] and the authors of this poster.

This study was funded by AstraZeneca and Daiichi Sankyo. In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (T-DXd; DS-8201) Poster presented at SABCS[®] 2023, December 5–9, San Antonio, TX, US, and virtually by Paul Cottu.

This presentation is the intellectual property of the author/presenter. Contact paul.cottu@curie.fr for permission to reprint and/or distribute.

Introduction

- Women with HER2+ mBC who experience progression after 1L therapy (trastuzumab, pertuzumab, and a taxane) typically require a subsequent LOT¹
- Trastuzumab emtansine (T-DM1) was standard of care in the 2L setting until the recent approval (July 2022 in the EU) of trastuzumab deruxtecan (T-DXd) after ≥1 anti-HER2 regimen²
- Receiving optimal targeted therapy in the earliest indicated setting is important to maximize the likelihood and durability of a clinical benefit³
- As new therapies become available, understanding treatment patterns by LOT may help guide treatment decision making and inform the optimal treatment paradigm for patients with HER2+ mBC

Results and interpretation

Methods

- In this ongoing multicenter observational study, electronic medical record (EMR) data were collected retrospectively from women ≥18 years old diagnosed with HER2+ mBC between 2017 and 2021, in EU4 countries and the UK
- Structured EMR data and manually abstracted unstructured data from oncology centers were curated. Patients had the opportunity to be followed up for ≥12 months from mBC diagnosis

The primary endpoint was attrition rate (percentage of patients who completed an LOT but did not receive the subsequent LOT) after 1L and 2L therapy

- An overview of how attrition rates were calculated and reasons for attrition are shown in Figure 1
- Documented reasons for attrition included death or move to end-of-life palliative care (within 30 days of end of LOT), discontinuation due to toxicity, end of study period, loss to FU, or 'other' if reasons did not meet these criteria, or if death or move to end-of-life palliative care occurred >30 days after treatment discontinuation
- This analysis included data from 496 women across seven sites in five countries: one in France, two in Germany, one in Italy, one in Spain, and two in the UK
- Data here are shown for all patients with HER2+ disease. Pooled data split according to hormone receptor status are available in supplementary material (**Supplementary figure 1 and 2**)
- Overall median duration of FU was 41.1 months (95% confidence interval [CI] 22.4, 52.8). A total of 59.1% of patients were postmenopausal, 60.9% had de-novo disease, 60.9% had Stage IV disease, and 27.4% had ≥4 metastatic sites. Overall, 41.9%, 26.4%, and 12.3% received a total number of one, two, and three LOTs per patient, respectively

Table 1. Patient demographics and clinical characteristics								
	France (N=115)	Germany (N=84)	Italy (N=105)	Spain (N=56)	UK (N=136)			
Median age at mBC diagnosis, years (Q1–Q3)	56.0 (46.0–71.0)	67.5 (57.0–76.0)	56.0 (47.0–63.0)	55.5 (49.0–68.0)	61.5 (49.0–73.0			
Median duration of FU, months (Q1–Q3)	38.8 (21.3–51.4)	24.4 (12.1–44.5)	45.4 (29.4–56.3)	40.9 (20.2–56.5)	44.0 (27.8–54.0			
Median BMI, kg/m² (Q1–Q3)	24.7 (22.0–28.6)	26.0 (23.0–29.1)	24.2 (22.1–28.8)	26.3 (23.6–30.1)	28.6 (24.3–31.9			
Postmenopausal status, n (%)	52 (45.2)	57 (67.9)	45 (42.9)	40 (71.4)	99 (72.8)			
Metastatic sites, n (%)								
<4	83 (72.2)	61 (72.6)	76 (72.4)	48 (85.7)	92 (67.7)			
≥4	32 (27.8)	23 (27.4)	29 (27.6)	8 (14.3)	44 (32.4)			
Metastatic location, n (%)*								
Brain	19 (16.5)	22 (26.2)	47 (44.8)	19 (33.9)	44 (32.4)			
Bone	69 (60.0)	54 (64.3)	58 (55.2)	35 (62.5)	69 (50.7)			
Lung	40 (34.8)	36 (42.9)	41 (39.1)	14 (25.0)	62 (45.6)			
Liver	48 (41.7)	44 (52.4)	47 (44.8)	20 (35.7)	70 (51.5)			
Lymph nodes	71 (61.7)	39 (46.4)	55 (52.4)	22 (39.3)	71 (52.2)			
De-novo disease, n (%)	76 (66.1)	48 (57.1)	58 (55.2)	30 (53.6)	90 (66.2)			
Stage, n (%) [†]								
O/I/II/III	35 (30.4)	30 (35.7)	34 (32.4)	26 (46.4)	44 (32.4)			
IV	76 (66.1)	48 (57.1)	58 (55.2)	30 (53.6)	90 (66.2)			
Total number of LOTs per patient, n (%) [‡]								
0	0	5 (6.0)	5 (4.8)	1 (1.8)	23 (16.9)			
1	44 (38.3)	44 (52.4)	47 (44.8)	26 (46.4)	47 (34.6)			
2	37 (32.2)	20 (23.8)	33 (31.4)	11 (19.6)	30 (22.1)			
3	17 (14.8)	6 (7.1)	11 (10.5)	11 (19.6)	16 (11.8)			

*Patients may belong to >1 category; †n=25 patients had 'unknown' or 'missing' staging information; ‡n=62 patients received ≥4 LOTs per patient BMI, body mass index; FU, follow up; LOT, line of therapy; mBC, metastatic breast cancer; Q, quartile

Table 2 Number of nationts starting 11 and 21 th

Table 2. Number of patients starting TL and 2L therapy									
	OVERALL (N=496)	France (N=115)	Germany (N=84)	Italy (N=105)	Spain (N=56)	UK (N=136)			
1L, n (%)	462 (93.1)	115 (100)	79 (94.0)	100 (95.2)	55 (98.2)	113 (83.1)			
2L, n (%)	254 (51.2)	71 (61.7)	35 (41.7)	53 (50.5)	29 (51.8)	66 (48.5)			


1L, first line; 2L, second line

References

1. Jiang H, Rugo HS. Ther Adv Med Oncol. 2015;7:321–339; 2. Enhertu (trastuzumab deruxtecan) summary of product characteristics. 2023. Available from: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-productinformation_en.pdf (Accessed October 27, 2023); 3. Bonotto M, et al. Oncologist. 2015;20:719–724


Disclosures

Paul Cottu reports funding from AstraZeneca; medical writing support from IQVIA; consulting fees from AstraZeneca, Daiichi Sankyo, Novartis, and Pfizer; payment/honoraria from Pfizer; and meeting/travel support from Daiichi Sankyo and Pfizer.




A, attrition; FU, follow up; HER2+, human epidermal growth factor receptor 2-positive; LOT, line of therapy; mBC, metastatic breast cancer; N, number of patients

Figure 2. Attrition rates between LOT



■ 1L to 2L ■ 2L to 3L

Figure 3. Reasons for attrition between LOT*



*Main drivers behind the 'other' reasons for attrition category will be reported in the manuscript

- to 3L, 9.4% [n=6]), toxicity (1L to 2L, 1.9% [n=2]; 2L to 3L, 4.7% [n=3]), loss to FU (1L to 2L, 14.0% [n=15]; 2L to 3L, 12.5% [n=8]), end of study period (1L to 2L, 1.9% [n=2]; 2L to 3L, 7.8% [n=5]), and 'other' (1L to 2L, 29.9% [n=32]; 2L to 3L, 40.6% [n=26]) (**Figure 3**)
- Further details on 'other' reasons for attrition can be found in supplementary material (**Supplementary figure 3**)

Acknowledaments

Medical writing support, under the direction of the authors, was provided by Carmen Grimaldos, PhD, of Helios Medical Communications, and was funded by AstraZeneca in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp-2022).